Extraerythrocytic hemoglobin - A possible oxygen transporter in human malignant tumors

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 580-583

  Bürgers, Anja C ^a   Lammert, Eckhard ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; EXTRAERYTHROCYTIC HEMOGLOBIN; HEMOGLOBIN; OXYGEN; UNCLASSIFIED DRUG;

ARTICLE; ENDOTHELIUM CELL; ERYTHROCYTE; HEMOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OXYGEN AFFINITY; OXYGEN TRANSPORT; PROGNOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR CELL; VASCULARIZATION;

ERYTHROCYTES; HEMOGLOBINS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, THEORETICAL; NEOPLASMS; OXYGEN;

EID: 80052635152     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.06.035     Document Type: Article

References (36)

1. Gerhardt H., Semb H. Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med 2008, 86(2):135-144.
2. Folkman J. Is angiogenesis an organizing principle in biology and medicine?. J Pediatr Surg 2007, 42(1):1-11.
3. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10(7):505-514.
4. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
5. Betsholtz C., Armulik A. Homeostatic functions of vascular endothelial growth factor in adult microvasculature. Am J Physiol Heart Circ Physiol 2006, 290(2):H509-H511.
6. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007, 101(4):937-949.
7. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor-2 negative metastatic breast cancer. J Clin Oncol 2010, 28(20):3239-3247.
8. Prat A., Casado E., Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007, 13(44):5857-5866.
9. Rini B.I. Vascular endothelial growth factor - Targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007, 13(4):1098-1106.
10. Jefferson E. FDA begins process to remove breast cancer indication from Avastin label, December 16, 2010. From [Retrieved December 20, 2010]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm.
11. Folberg R., Rummelt V., Parys-Van Ginderdeuren R., et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993, 100(9):1389-1398.
12. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155(3):739-752.
13. Kučera T., Lammert E. Ancestral vascular tube formation and its adoption by tumors. Biol Chem 2009, 390(10):985-994.
14. Kamba T., Tam B.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006, 290(2):H560-H576.
15. Folberg R., Maniotis A.J. Vasculogenic mimicry. APMIS 2004, 112(7-8):508-525.
16. Sood A.K., Fletcher M.S., Zahn C.M., et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 2002, 1(6):661-664.
17. Sun B., Zhang S., Zhang D., et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006, 16(4):693-698.
18. Vartanian A.A., Stepanova E.V., Gutorov S.L., et al. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol 2009, 16(4):4726-4732.
19. Baeten C.I., Hillen F., Pauwels P., de Bruine A.P., Baeten C.G. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 2009, 52(12):2028-2035.
20. Sun B., Qie S., Zhang S., et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008, 39(3):444-451.
21. Lohrmann H.P., Adam W., Heymer B., Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973, 79(3):368-375.
22. Levy A.P., Asleh R., Blum S., et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010, 12(2):293-304.
23. Shirakawa K., Kobayashi H., Heike Y., et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002, 62(2):560-566.
24. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3(6):411-421.
25. Clarijs R., Otte-Höller I., Ruiter D.J., de Waal R.M. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 2002, 43(4):912-918.
26. Terwilliger N.B. Functional adaptations of oxygen-transport proteins. J Exp Biol 1998, 201(Pt 8):1085-1098.
27. Mangum C.P. Oxygen transport in invertebrates. Am J Physiol 1985, 248(5 Pt 2):R505-R514.
28. Duke University Medical Center. Lactic acid found to fuel tumors. Science Daily 2008, November 23. From [Retrieved July 2, 2010]. http://www.sciencedaily.com/releases/2008/11/081120171325.htm.
29. Creteur J., Sibbald W., Vincent J.L. Hemoglobin solutions - Not just red blood cell substitutes. Crit Care Med 2000, 28(8):3025-3034.
30. Shirakawa K., Tsuda H., Heike Y., et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001, 61(2):445-451.
31. Bhagwati N., Seno R., Dutcher J.P., Oleksowicz L. Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia. Hematopathol Mol Hematol 1998, 11(2):101-108.
32. Horne M.K., Cooper B. Microangiopathic hemolytic anemia with metastatic adenocarcinoma: response to chemotherapy. South Med J 1982, 75(4):503-504.
33. Seo D.W., Lee Y.S., Chae J.G., et al. Hepatocellular carcinoma associated hemolytic uremic syndrome unrelated to chemotherapy. J Korean Med Sci 1994, 9(3):254-258.
34. Sosman J., Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009, 115(Suppl. 10):2368-2375.
35. Rini B.I., Garcia J.A., Cooney M.M., et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010, 28(17):e284-e285.
36. Kressel B.R., Ryan K.P., Duong A.T., Berenberg J., Schein P.S. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 1981, 48(8):1738-1745.